Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study

DOI record: { "DOI": "10.1016/j.jinf.2023.02.012", "ISSN": [ "0163-4453" ], "URL": "http://dx.doi.org/10.1016/j.jinf.2023.02.012", "alternative-id": [ "S0163445323000828" ], "assertion": [ { "label": "This article is maintained by", "name": "publisher", "value": "Elsevier" }, { "label": "Article Title", "name": "articletitle", "value": "Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study" }, { "label": "Journal Title", "name": "journaltitle", "value": "Journal of Infection" }, { "label": "CrossRef DOI link to publisher maintained version", "name": "articlelink", "value": "https://doi.org/10.1016/j.jinf.2023.02.012" }, { "label": "Content Type", "name": "content_type", "value": "article" }, { "label": "Copyright", "name": "copyright", "value": "Crown Copyright © 2023 Published by Elsevier Ltd on behalf of The British Infection Association. All rights reserved." } ], "author": [ { "affiliation": [], "family": "Evans", "given": "Andrew", "sequence": "first" }, { "affiliation": [], "family": "Qi", "given": "Cathy", "sequence": "additional" }, { "affiliation": [], "family": "Adebayo", "given": "Jubril Omololu", "sequence": "additional" }, { "affiliation": [], "family": "Underwood", "given": "Jonathan", "sequence": "additional" }, { "affiliation": [], "family": "Coulson", "given": "James", "sequence": "additional" }, { "affiliation": [], "family": "Bailey", "given": "Rowena", "sequence": "additional" }, { "affiliation": [], "family": "Lyons", "given": "Ronan", "sequence": "additional" }, { "affiliation": [], "family": "Edwards", "given": "Adrian", "sequence": "additional" }, { "affiliation": [], "family": "Cooper", "given": "Alison", "sequence": "additional" }, { "affiliation": [], "family": "John", "given": "Gareth", "sequence": "additional" }, { "affiliation": [], "family": "Akbari", "given": "Ashley", "sequence": "additional" } ], "container-title": "Journal of Infection", "container-title-short": "Journal of Infection", "content-domain": { "crossmark-restriction": true, "domain": [ "clinicalkey.fr", "clinicalkey.jp", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.com", "journalofinfection.com", "elsevier.com", "sciencedirect.com" ] }, "created": { "date-parts": [ [ 2023, 2, 10 ] ], "date-time": "2023-02-10T10:47:06Z", "timestamp": 1676026026000 }, "deposited": { "date-parts": [ [ 2023, 2, 24 ] ], "date-time": "2023-02-24T15:41:42Z", "timestamp": 1677253302000 }, "indexed": { "date-parts": [ [ 2023, 2, 25 ] ], "date-time": "2023-02-25T05:30:36Z", "timestamp": 1677303036165 }, "is-referenced-by-count": 1, "issued": { "date-parts": [ [ 2023, 2 ] ] }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 2, 1 ] ], "date-time": "2023-02-01T00:00:00Z", "timestamp": 1675209600000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S0163445323000828?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S0163445323000828?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "prefix": "10.1016", "published": { "date-parts": [ [ 2023, 2 ] ] }, "published-print": { "date-parts": [ [ 2023, 2 ] ] }, "publisher": "Elsevier BV", "reference": [ { "key": "10.1016/j.jinf.2023.02.012_bib1", "unstructured": "Department of Health and Social Care. Government launches COVID-19 antivirals taskforce to roll out innovative home treatments this autumn; 2021 [cited 2023 Jan 20]. Available from: 〈https://www.gov.uk/government/news/government-launches-covid-19-antivirals-taskforce-to-roll-out-innovative-home-treatments-this-autumn〉." }, { "DOI": "10.1056/NEJMoa2107934", "article-title": "Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab", "author": "Gupta", "doi-asserted-by": "crossref", "first-page": "1941", "journal-title": "N Engl J Med", "key": "10.1016/j.jinf.2023.02.012_bib2", "volume": "385", "year": "2021" }, { "DOI": "10.1056/NEJMoa2116044", "article-title": "Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients", "author": "Jayk Bernal", "doi-asserted-by": "crossref", "first-page": "509", "journal-title": "N Engl J Med", "key": "10.1016/j.jinf.2023.02.012_bib3", "volume": "386", "year": "2022" }, { "DOI": "10.1056/NEJMoa2118542", "article-title": "Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19", "author": "Hammond", "doi-asserted-by": "crossref", "first-page": "1397", "journal-title": "N Engl J Med", "key": "10.1016/j.jinf.2023.02.012_bib4", "volume": "386", "year": "2022" }, { "DOI": "10.1056/NEJMoa2116846", "article-title": "Early remdesivir to prevent progression to severe Covid-19 in outpatients", "author": "Gottlieb", "doi-asserted-by": "crossref", "first-page": "305", "journal-title": "N Engl J Med", "key": "10.1016/j.jinf.2023.02.012_bib5", "volume": "386", "year": "2022" }, { "DOI": "10.1056/NEJMoa2108163", "article-title": "REGEN-COV antibody combination and outcomes in outpatients with Covid-19", "author": "Weinreich", "doi-asserted-by": "crossref", "issue": "23", "journal-title": "N Engl J Med", "key": "10.1016/j.jinf.2023.02.012_bib6", "volume": "385", "year": "2021" }, { "article-title": "COVID-19 Genomics UK Consortium,et al., SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies", "author": "Cox", "first-page": "1", "journal-title": "Nat Rev Microbiol", "key": "10.1016/j.jinf.2023.02.012_bib7", "year": "2022" }, { "key": "10.1016/j.jinf.2023.02.012_bib8", "unstructured": "Roche. Ronapreve does not retain neutralising activity against the Omicron variant; 2021 [cited 2023 Jan 20] [internet]. Available from: 〈2021216_roche-statement-on-ronapreve-omicron.pdf〉." }, { "key": "10.1016/j.jinf.2023.02.012_bib9", "unstructured": "US Federal Drugs Administration. Coronavirus (COVID-19) update: FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the Omicron variant; 2022 [cited 2023 Jan 20] [internet]. Available from: 〈https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron〉." }, { "key": "10.1016/j.jinf.2023.02.012_bib10", "unstructured": "World Health Organisation. Therapeutics and COVID-19: living guideline; 2022 [cited 2023 Jan 20] [internet]. Available from: 〈https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.5〉." }, { "key": "10.1016/j.jinf.2023.02.012_bib11", "unstructured": "Department of Health and Social Care. Highest-risk patients eligible for new COVID-19 treatments: a guide for patients; 2022 [cited 2023 Jan 20]. Available from: 〈https://www.gov.uk/government/publications/highest-risk-patients-eligible-for-covid-19-treatments-guide-for-patients/highest-risk-patients-eligible-for-new-covid-19-treatments-a-guide-for-patients〉." }, { "key": "10.1016/j.jinf.2023.02.012_bib12", "unstructured": "NHS England. Interim clinical commissioning policy: treatments for non-hospitalised patients with COVID-19; 2022 [cited 2023 Jan 20] [internet]. Available from: 〈C1710-interim-clinical-commissioning-policy-treatments-for-non-hospitalised-patients-with-covid-19-nov-22.pdf〉 (england.nhs.uk)." }, { "key": "10.1016/j.jinf.2023.02.012_bib13", "unstructured": "NHS England. COVID-19 therapeutics (antivirals, neutralising monoclonal antibodies and interleukin 6 inhibitors); 2022 [cited 2023 Jan 20] [internet]. Available from: 〈https://www.england.nhs.uk/statistics/statistical-work-areas/covid-therapeutics-antivirals-and-neutralising-monoclonal-antibodies/〉." }, { "key": "10.1016/j.jinf.2023.02.012_bib14", "unstructured": "Welsh Government. Weekly COVID-19 treatment counts by therapeutic agent in Wales; 2022 [cited 2023 Jan 20] [internet]. Available from: 〈https://statswales.gov.wales/Catalogue/Health-and-Social-Care/coronavirus-covid-19/covid-19-treatments-by-therapeutic-agent/weeklycovidtreatmentcounts-by-therapeuticagent〉." }, { "DOI": "10.1186/1472-6963-9-157", "article-title": "The SAIL databank: building a national architecture for e-health research and evaluation", "author": "Ford", "doi-asserted-by": "crossref", "first-page": "157", "journal-title": "BMC Health Serv Res", "key": "10.1016/j.jinf.2023.02.012_bib15", "volume": "9", "year": "2009" }, { "DOI": "10.1016/j.jbi.2014.01.003", "article-title": "A case study of the secure anonymous information linkage (SAIL) gateway: a privacy protecting remote access system for health related research and evaluation", "author": "Jones", "doi-asserted-by": "crossref", "first-page": "196", "issue": "100", "journal-title": "J Biomed Inform", "key": "10.1016/j.jinf.2023.02.012_bib16", "volume": "50", "year": "2014" }, { "DOI": "10.1186/1472-6947-9-3", "article-title": "The SAIL databank: linking multiple health and social care datasets", "author": "Lyons", "doi-asserted-by": "crossref", "first-page": "3", "journal-title": "BMC Med Inform Decis Mak", "key": "10.1016/j.jinf.2023.02.012_bib17", "volume": "9", "year": "2009" }, { "DOI": "10.1016/j.healthplace.2011.09.006", "article-title": "Protecting health data privacy while using residence-based environment and demographic data", "author": "Rodgers", "doi-asserted-by": "crossref", "first-page": "209", "issue": "2", "journal-title": "Health Place", "key": "10.1016/j.jinf.2023.02.012_bib18", "volume": "18", "year": "2012" }, { "DOI": "10.1093/pubmed/fdp041", "article-title": "Residential anonymous linking fields (RALFs): a novel information infrastructure to study the interaction between the environment and individuals’ health", "author": "Rodgers", "doi-asserted-by": "crossref", "first-page": "582", "issue": "4", "journal-title": "J Public Health", "key": "10.1016/j.jinf.2023.02.012_bib19", "volume": "31", "year": "2009" }, { "key": "10.1016/j.jinf.2023.02.012_bib20", "unstructured": "Welsh Government. Coronavirus (COVID-19) infection survey (positivity estimates): 27 March to 2 April 2022; 2022 [cited 2023 Jan 20] [internet]. Available from: 〈https://www.gov.wales/coronavirus-covid-19-infection-survey-positivity-estimates-27-march-2-april-2022-html〉." }, { "key": "10.1016/j.jinf.2023.02.012_bib21", "unstructured": "Welsh Medicines Information Centre. National Antiviral Service Cymru (NAVS) – information for members of the public; 2022 [cited 2023 Jan 20]. Available from: 〈https://www.wmic.wales.nhs.uk/navs-cymru/#:~:text=%E2%80%93%20Information%20for%20Members%20of%20the,not%20been%20admitted%20to%20hospital〉." }, { "article-title": "Effectiveness of paxlovid in reducing severe COVID-19 and mortality in high risk patients", "author": "Najjar-Debbiny", "journal-title": "Clin Infect Dis", "key": "10.1016/j.jinf.2023.02.012_bib22", "year": "2022" }, { "DOI": "10.1101/2022.09.07.22279497", "doi-asserted-by": "crossref", "key": "10.1016/j.jinf.2023.02.012_bib23", "unstructured": "Cheng M, Reyes C, Satram S, H. Birch, D.C. Gibbons, M. Drysdale, et al. Real-world effectiveness of sotrovimab for the early treatment of COVID-19 during SARS-CoV-2 Delta and Omicron waves in the United States. [Preprint]. medRxiv 2022.09.07.22279497." }, { "DOI": "10.1093/jac/dkac256", "article-title": "Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge", "author": "Piccicacco", "doi-asserted-by": "crossref", "first-page": "2693", "issue": "10", "journal-title": "J Antimicrob Chemother", "key": "10.1016/j.jinf.2023.02.012_bib24", "volume": "77", "year": "2022" }, { "article-title": "Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial", "author": "Butler", "journal-title": "Lancet", "key": "10.1016/j.jinf.2023.02.012_bib25", "year": "2022" }, { "article-title": "Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform", "author": "Zheng", "journal-title": "BMJ", "key": "10.1016/j.jinf.2023.02.012_bib26", "volume": "379", "year": "2022" }, { "article-title": "Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England", "author": "Patel", "journal-title": "medRxiv", "key": "10.1016/j.jinf.2023.02.012_bib27", "year": "2022" }, { "DOI": "10.1111/ajt.17098", "article-title": "Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge", "author": "Radcliffe", "doi-asserted-by": "crossref", "first-page": "2458", "journal-title": "Am J Transplant", "key": "10.1016/j.jinf.2023.02.012_bib28", "volume": "22", "year": "2022" }, { "DOI": "10.1016/S0140-6736(22)01938-9", "article-title": "WHO’s therapeutics and COVID-19 living guideline on mAbs needs to be reassessed", "author": "Wu", "doi-asserted-by": "crossref", "journal-title": "Lancet", "key": "10.1016/j.jinf.2023.02.012_bib29", "year": "2022" }, { "DOI": "10.1038/d41586-021-03667-0", "article-title": "Merck’s COVID pill loses its lustre: what that means for the pandemic", "author": "Koslov", "doi-asserted-by": "crossref", "journal-title": "Nature", "key": "10.1016/j.jinf.2023.02.012_bib30", "year": "2021" }, { "key": "10.1016/j.jinf.2023.02.012_bib31", "unstructured": "Office for National Statistics. Coronavirus (COVID-19) latest insights: hospitals; 2023 [cited 2023 Jan 20] [internet]. Available from: 〈https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/hospitals〉." }, { "key": "10.1016/j.jinf.2023.02.012_bib32", "unstructured": "The National Institute for Health and Care Excellence. Draft guidance consultation: therapeutics for people with COVID-19; 2022 [cited 2023 Jan 20] [internet]. Available from: 〈https://www.nice.org.uk/guidance/gid-ta10936/documents/129〉." }, { "key": "10.1016/j.jinf.2023.02.012_bib33", "unstructured": "The Institute for Clinical and Economic Review. Report at a glance: COVID-19; 2022 [cited 2023 Jan 20]. Available from: 〈https://icer.org/wp-content/uploads/2022/05/COVID-19-RAAG_10May2022.pdf〉." } ], "reference-count": 33, "references-count": 33, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S0163445323000828" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Infectious Diseases", "Microbiology (medical)" ], "subtitle": [], "title": "Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy" }